These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1479 related articles for article (PubMed ID: 28373005)
1. Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial. Gulley JL; Rajan A; Spigel DR; Iannotti N; Chandler J; Wong DJL; Leach J; Edenfield WJ; Wang D; Grote HJ; Heydebreck AV; Chin K; Cuillerot JM; Kelly K Lancet Oncol; 2017 May; 18(5):599-610. PubMed ID: 28373005 [TBL] [Abstract][Full Text] [Related]
2. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Patel MR; Ellerton J; Infante JR; Agrawal M; Gordon M; Aljumaily R; Britten CD; Dirix L; Lee KW; Taylor M; Schöffski P; Wang D; Ravaud A; Gelb AB; Xiong J; Rosen G; Gulley JL; Apolo AB Lancet Oncol; 2018 Jan; 19(1):51-64. PubMed ID: 29217288 [TBL] [Abstract][Full Text] [Related]
4. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study. Barlesi F; Vansteenkiste J; Spigel D; Ishii H; Garassino M; de Marinis F; Özgüroğlu M; Szczesna A; Polychronis A; Uslu R; Krzakowski M; Lee JS; Calabrò L; Arén Frontera O; Ellers-Lenz B; Bajars M; Ruisi M; Park K Lancet Oncol; 2018 Nov; 19(11):1468-1479. PubMed ID: 30262187 [TBL] [Abstract][Full Text] [Related]
5. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA; Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095 [TBL] [Abstract][Full Text] [Related]
6. Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial. Choueiri TK; Larkin J; Oya M; Thistlethwaite F; Martignoni M; Nathan P; Powles T; McDermott D; Robbins PB; Chism DD; Cho D; Atkins MB; Gordon MS; Gupta S; Uemura H; Tomita Y; Compagnoni A; Fowst C; di Pietro A; Rini BI Lancet Oncol; 2018 Apr; 19(4):451-460. PubMed ID: 29530667 [TBL] [Abstract][Full Text] [Related]
7. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Kaufman HL; Russell J; Hamid O; Bhatia S; Terheyden P; D'Angelo SP; Shih KC; Lebbé C; Linette GP; Milella M; Brownell I; Lewis KD; Lorch JH; Chin K; Mahnke L; von Heydebreck A; Cuillerot JM; Nghiem P Lancet Oncol; 2016 Oct; 17(10):1374-1385. PubMed ID: 27592805 [TBL] [Abstract][Full Text] [Related]
8. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Antonia S; Goldberg SB; Balmanoukian A; Chaft JE; Sanborn RE; Gupta A; Narwal R; Steele K; Gu Y; Karakunnel JJ; Rizvi NA Lancet Oncol; 2016 Mar; 17(3):299-308. PubMed ID: 26858122 [TBL] [Abstract][Full Text] [Related]
9. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial. Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962 [TBL] [Abstract][Full Text] [Related]
10. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Rosenberg JE; Hoffman-Censits J; Powles T; van der Heijden MS; Balar AV; Necchi A; Dawson N; O'Donnell PH; Balmanoukian A; Loriot Y; Srinivas S; Retz MM; Grivas P; Joseph RW; Galsky MD; Fleming MT; Petrylak DP; Perez-Gracia JL; Burris HA; Castellano D; Canil C; Bellmunt J; Bajorin D; Nickles D; Bourgon R; Frampton GM; Cui N; Mariathasan S; Abidoye O; Fine GD; Dreicer R Lancet; 2016 May; 387(10031):1909-20. PubMed ID: 26952546 [TBL] [Abstract][Full Text] [Related]
11. Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial. Smit EF; Felip E; Uprety D; Nagasaka M; Nakagawa K; Paz-Ares Rodríguez L; Pacheco JM; Li BT; Planchard D; Baik C; Goto Y; Murakami H; Saltos A; Pereira K; Taguchi A; Cheng Y; Yan Q; Feng W; Tsuchihashi Z; Jänne PA Lancet Oncol; 2024 Apr; 25(4):439-454. PubMed ID: 38547891 [TBL] [Abstract][Full Text] [Related]
12. Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial. Schöffski P; Sufliarsky J; Gelderblom H; Blay JY; Strauss SJ; Stacchiotti S; Rutkowski P; Lindner LH; Leahy MG; Italiano A; Isambert N; Debiec-Rychter M; Sciot R; Van Cann T; Marréaud S; Nzokirantevye A; Collette S; Wozniak A Lancet Respir Med; 2018 Jun; 6(6):431-441. PubMed ID: 29669701 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial. Disis ML; Taylor MH; Kelly K; Beck JT; Gordon M; Moore KM; Patel MR; Chaves J; Park H; Mita AC; Hamilton EP; Annunziata CM; Grote HJ; von Heydebreck A; Grewal J; Chand V; Gulley JL JAMA Oncol; 2019 Mar; 5(3):393-401. PubMed ID: 30676622 [TBL] [Abstract][Full Text] [Related]
14. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Alley EW; Lopez J; Santoro A; Morosky A; Saraf S; Piperdi B; van Brummelen E Lancet Oncol; 2017 May; 18(5):623-630. PubMed ID: 28291584 [TBL] [Abstract][Full Text] [Related]
15. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. Gettinger SN; Bazhenova LA; Langer CJ; Salgia R; Gold KA; Rosell R; Shaw AT; Weiss GJ; Tugnait M; Narasimhan NI; Dorer DJ; Kerstein D; Rivera VM; Clackson T; Haluska FG; Camidge DR Lancet Oncol; 2016 Dec; 17(12):1683-1696. PubMed ID: 27836716 [TBL] [Abstract][Full Text] [Related]
16. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial. Friedlander M; Meniawy T; Markman B; Mileshkin L; Harnett P; Millward M; Lundy J; Freimund A; Norris C; Mu S; Wu J; Paton V; Gao B Lancet Oncol; 2019 Sep; 20(9):1306-1315. PubMed ID: 31378459 [TBL] [Abstract][Full Text] [Related]
17. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study. Pujade-Lauraine E; Fujiwara K; Ledermann JA; Oza AM; Kristeleit R; Ray-Coquard IL; Richardson GE; Sessa C; Yonemori K; Banerjee S; Leary A; Tinker AV; Jung KH; Madry R; Park SY; Anderson CK; Zohren F; Stewart RA; Wei C; Dychter SS; Monk BJ Lancet Oncol; 2021 Jul; 22(7):1034-1046. PubMed ID: 34143970 [TBL] [Abstract][Full Text] [Related]
18. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Shaw AT; Kim TM; Crinò L; Gridelli C; Kiura K; Liu G; Novello S; Bearz A; Gautschi O; Mok T; Nishio M; Scagliotti G; Spigel DR; Deudon S; Zheng C; Pantano S; Urban P; Massacesi C; Viraswami-Appanna K; Felip E Lancet Oncol; 2017 Jul; 18(7):874-886. PubMed ID: 28602779 [TBL] [Abstract][Full Text] [Related]
19. Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial. Gao X; Xu N; Li Z; Shen L; Ji K; Zheng Z; Liu D; Lou H; Bai L; Liu T; Li Y; Li Y; Fan Q; Feng M; Zhong H; Huang Y; Lou G; Wang J; Lin X; Chen Y; An R; Li C; Zhou Q; Huang X; Guo Z; Wang S; Li G; Fei J; Zhu L; Zhu H; Li X; Li F; Liao S; Min Q; Tang L; Shan F; Gong J; Gao Y; Zhou J; Lu Z; Li X; Li J; Ren H; Liu X; Yang H; Li W; Song W; Wang ZM; Li B; Xia M; Wu X; Ji J Lancet Oncol; 2023 Oct; 24(10):1134-1146. PubMed ID: 37797632 [TBL] [Abstract][Full Text] [Related]
20. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study. Schuler M; Cho BC; Sayehli CM; Navarro A; Soo RA; Richly H; Cassier PA; Tai D; Penel N; Nogova L; Park SH; Schostak M; Gajate P; Cathomas R; Rajagopalan P; Grevel J; Bender S; Boix O; Nogai H; Ocker M; Ellinghaus P; Joerger M Lancet Oncol; 2019 Oct; 20(10):1454-1466. PubMed ID: 31405822 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]